Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Iran And NotGhazaleh Zarrinrad

List of bibliographic references

Number of relevant bibliographic references: 22.
Ident.Authors (with country if any)Title
000041 Hadir Shakshouk [États-Unis, Égypte] ; Maryam Daneshpazhooh [Iran] ; Dedee F. Murrell [Australie] ; Julia S. Lehman [États-Unis]Treatment considerations for patients with pemphigus during the COVID-19 pandemic
000059 Banafsheh Mosharmovahed [Iran] ; Yousef Fatahi [Iran] ; Bahareh Mohebbi [Iran] ; Sohrab Ali Ghorbanian [Iran] ; Sara Assadiasl [Iran]Tocilizumab in transplantation.
000106 Akram Aminjafari [Iran] ; Sorayya Ghasemi [Iran]The Possible of Immunotherapy for COVID-19: a Systematic Review
000216 Elaheh Kordzadeh-Kermani [Iran] ; Hossein Khalili [Iran] ; Iman Karimzadeh [Iran] ; Mohammadreza Salehi [Iran]Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators
000225 Ali Rismanbaf [Iran]Potential Treatments for COVID-19; a Narrative Literature Review
000334 Amin Gasmi [France] ; Sadaf Noor [Pakistan] ; Torsak Tippairote [Thaïlande] ; Maryam Dadar [Iran] ; Alain Menzel [France] ; Geir Bj Rklund [Norvège]Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
000395 Mohsen Jari [Iran] ; Reza Shiari [Iran] ; Omid Salehpour [Iran] ; Khosro Rahmani [Iran]Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis
000475 Farzaneh Dastan [Iran] ; Ali Saffaei [Iran] ; Seyed Mehdi Mortazavi [Iran] ; Hamidreza Jamaati [Iran] ; Nadia Adnani [Iran] ; Sasan Samiee Roudi [Iran] ; Arda Kiani [Iran] ; Atefeh Abedini [Iran] ; Seyed Mohammadreza Hashemian [Iran]Continues Renal Replacement Therapy (CRRT) With Disposable Hemoperfusion Cartridge: A Promising Option for Severe COVID-19
000565 Ali Aminian [États-Unis] ; Mohammad Kermansaravi [Iran] ; Shahriar Azizi [Iran] ; Peyman Alibeigi [Iran] ; Sina Safamanesh [Iran] ; Ali Mousavimaleki [Iran] ; Mohammad Taghi Rezaei [Iran] ; Maziar Faridi [Iran] ; Somayeh Mokhber [Iran] ; Abdolreza Pazouki [Iran] ; Saeed Safari [Iran]Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak
000948 Fatemeh Sanie-Jahromi [Iran] ; Masoomeh Eghtedari [Iran] ; Esmaeil Mirzaei [Iran] ; Mohammad Hassan Jalalpour [Iran] ; Zahra Asvar [Iran] ; Mahmood Nejabat [Iran] ; Fahimeh Javidi-Azad [Iran]Propagation of limbal stem cells on polycaprolactone and polycaprolactone/gelatin fibrous scaffolds and transplantation in animal model
000C05 Xiaoying Sun [République populaire de Chine] ; Raheleh Roudi [Iran] ; Ting Dai [République populaire de Chine] ; Shangya Chen ; Bin Fan [République populaire de Chine] ; Hongjin Li [République populaire de Chine] ; Yaqiong Zhou [République populaire de Chine] ; Min Zhou [République populaire de Chine] ; Bo Zhu [États-Unis] ; Chengqian Yin [États-Unis] ; Bin Li [République populaire de Chine] ; Xin Li [République populaire de Chine]Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
001775 Forouhe Zahir-Jouzdani [Iran] ; Fatemeh Atyabi [Iran] ; Nazanin MojtabaviInterleukin-6 participation in pathology of ocular diseases.
001817 Arman Ahmadzadeh [Iran] ; Alireza N. Farahmand [Iran] ; Latif Gachkar [Iran]Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
001C14 Amir Hashemi-Meshkini [Iran] ; Shekoufeh Nikfar [Iran] ; Elizabeth Glaser [États-Unis] ; Ahmadreza Jamshidi [Iran] ; Seyed Alireza Hosseini [Iran]Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model.
001F10 Mohammed Hammoudeh [Qatar] ; Adel Al Awadhi [Koweït] ; Eman Haji Hasan [Koweït] ; Maassoumeh Akhlaghi [Iran] ; Arman Ahmadzadeh [Iran] ; Bahar Sadeghi Abdollahi [Iran]Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East.
002125 Haydarali Esmaili [Iran] ; Elmira Mostafidi [Iran] ; Bahareh Mehramuz [Iran] ; Mohammadreza Ardalan [Iran] ; Mohammadali Mohajel-Shoja [États-Unis]An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
002168 Rosanna Abbate [Italie] ; Nasser M. Al-Daghri [Arabie saoudite] ; Paolo Andreozzi [Italie] ; Niels Borregaard [Danemark] ; Günay Can [Turquie] ; Gianluca Caridi [Italie] ; Maren Carstensen-Kirberg [Allemagne] ; Gabriele Cioni [Italie] ; Enrico Conte [Italie] ; Rosario Cuomo [Italie] ; Marie A. Denis [Belgique] ; Gohar Fakhfouri [Canada] ; G. Fakhfouri [Canada] ; Renné Fiasse [Belgique] ; Andreas Glenth J [Danemark] ; Georg Goliasch [Autriche] ; Thomas Gremmel [Autriche, États-Unis] ; Christian Herder [Allemagne] ; Maria Iemmolo [Italie] ; Zhi-Cheng Jing [République populaire de Chine] ; Robert Krause [Autriche] ; Oreste Marrone [Italie] ; Bartosz Miazgowski [Pologne] ; Tomasz Miazgowski [Pologne] ; Lorenzo Minchiotti [Italie] ; Kazem Mousavizadeh [Iran] ; Gjin Ndrepepa [Allemagne] ; Alexander Niessner [Autriche] ; Cristina Ogayar Luque [Espagne] ; Altan Onat [Turquie] ; Ioannis Papassotiriou [Grèce] ; Martín Ruiz Ortiz [Espagne] ; Shaun Sabico [Arabie saoudite] ; C. Mary Schooling [États-Unis] ; Sophia D. Sakka [Royaume-Uni] ; P. Sołtysiak [Pologne] ; Frank L. J. Visseren [Pays-Bas] ; Jasmin Wagner [Autriche] ; Xiao-Jian Wang [République populaire de Chine] ; Jan Westerink [Pays-Bas]Research update for articles published in EJCI in 2013
002546 Gholamreza Azizi [Iran] ; Roobina Boghozian [Iran] ; Abbas Mirshafiey [Iran]The potential role of angiogenic factors in rheumatoid arthritis
002787 Seema Kalra [Royaume-Uni] ; Alan Silman [Royaume-Uni] ; Gulsen Akman-Demir [Turquie] ; Saeed Bohlega [Arabie saoudite] ; Afshin Borhani-Haghighi [Iran] ; Cris S. Constantinescu [Royaume-Uni] ; Habib Houman [Tunisie] ; Alfred Mahr [France] ; Carlos Salvarani [Italie] ; Petros P. Sfikakis [Grèce] ; Aksel Siva [Turquie] ; Adnan Al-Araji [Royaume-Uni]Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations
003A53 Kamal Esalatmanesh [Iran] ; Raika Jamali [Iran] ; Arsia Jamali [Iran] ; Bardia Jamali [Iran] ; Mohammadreza Nikbakht [Iran]Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis
003A54 Batool Zamani [Iran] ; Raika Jamali [Iran] ; Arsia Jamali [Iran]Serum adenosine deaminase may predict disease activity in rheumatoid arthritis
003D52 Afshin Borhani Haghighi [Iran] ; Anahid Safari [Iran]Proposing an algorithm for treatment of different manifestations of neuro-Behcet’s disease
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021